ACT-PRESTO: Biological Tissue Clearing and Immunolabeling Methods for Volume Imaging
December 31st, 2016
14K views
ACT-PRESTO (active clarity technique–pressure related efficient and stable transfer of macromolecules into organs) enables rapid, efficient, but inexpensive tissue clearing and rapid antibody penetration into cleared tissues by passive diffusion or pressure-assisted delivery. Using this method, a wide range of tissues can be cleared, immunolabeled by multiple antibodies, and volume-imaged.
Overview
ACT-PRESTO is a novel technique for efficient tissue clearing and antibody penetration, enabling detailed visualization of molecular information in cleared tissues. This method facilitates sub-cellular level analysis of large specimens without the need for sectioning.
Key Study Components
Area of Science
- Neuroscience
- Developmental Biology
Background
- ACT-PRESTO allows for rapid and inexpensive tissue clearing.
- This technique supports immunolabeling with multiple antibodies.
- It enhances the depth of labeling in large tissues.
- Sub-cellular analysis is possible without sectioning the tissue.
Purpose of Study
- To visualize three-dimensional molecular information in tissues.
- To investigate neuronal connections and structural changes during development.
- To improve antibody penetration in dense tissues.
Methods Used
- Incubation of fixed organs in Hydrogel monomer solution.
- Use of a syringe pump for antibody delivery.
- Application of centrifugal forces to enhance antibody penetration.
- Immunolabeling of various mouse organs.
Main Results
- Enhanced labeling depth in kidney and liver tissues.
- Depth of labeling reached 300-350 micrometers in PRESTO samples.
- Significant improvement over conventional methods.
- Techniques can be completed within a day if performed correctly.
Conclusions
- ACT-PRESTO is a powerful tool for tissue analysis in medical research.
- It enables detailed studies of cellular dynamics and neuronal structures.
- Proper handling of Hydrogel solutions is crucial for safety.
Frequently Asked Questions
What is ACT-PRESTO?
ACT-PRESTO is a technique for efficient tissue clearing and antibody penetration, allowing for detailed molecular visualization.
How does ACT-PRESTO improve antibody penetration?
It uses passive diffusion and pressure-assisted delivery methods to enhance antibody penetration in dense tissues.
What are the advantages of using ACT-PRESTO?
The main advantages include rapid processing, cost-effectiveness, and the ability to analyze large specimens without sectioning.
What types of tissues can be analyzed using this method?
A wide range of tissues, including mouse organs like the brain, kidneys, and liver, can be analyzed.
How long does the ACT-PRESTO procedure take?
The procedure can be completed within a day if performed properly, with tissue clearing taking approximately 5-6 hours.
What precautions should be taken when using Hydrogel solutions?
Hydrogel monomer solutions can be hazardous, so appropriate safety measures should always be followed.
Executive Industry Relevance
ACT-PRESTO enables rapid, reproducible tissue clearing and deep immunolabeling for high-resolution 3D imaging of intact biological specimens. This capability addresses a critical bottleneck in discovery-stage research by preserving spatial molecular information and accelerating the interrogation of complex tissue architectures. The method supports translational continuity from early discovery through preclinical model development by enabling robust molecular mapping in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Facilitates comprehensive molecular and structural mapping in intact tissues for target validation.
- Enables functional de-risking by revealing cellular organization and molecular distribution without sectioning artifacts.
- Supports predictive confidence in target engagement and pathway analysis through volumetric immunolabeling.
Screening & Assay Development
- Prepares cleared, immunolabeled tissues as validated systems for downstream screening workflows.
- Delivers standardized, reproducible immunolabeling depth for quantitative assay development.
- Enables scalable preparation of large tissue samples for high-content imaging and analysis.
Translational & Preclinical Research
- Aligns molecular imaging outputs with disease-relevant tissue models for translational biomarker studies.
- Maintains spatial context for preclinical validation of therapeutic hypotheses.
- Reduces risk of information loss during tissue processing, supporting robust preclinical decision-making.
Pipeline & Workflow Integration
ACT-PRESTO integrates at the interface of discovery biology and preclinical research, enabling seamless transition from molecular hypothesis testing to in-depth tissue analysis.
- Discovery Biology: Supports hypothesis-driven mapping of molecular and cellular features in intact organs.
- Screening: Provides reproducible, quantitative immunolabeling for assay standardization and compound evaluation.
- Analytics: Generates high-resolution 3D datasets for comparative analysis of experimental conditions.
- Translational Research: Preserves disease-relevant tissue architecture for biomarker alignment and validation.
- Enterprise Reuse: Establishes a rapid, scalable protocol adaptable across diverse tissue types and research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in tissue-based studies.
- Operational Value: Delivers rapid, standardized, and reproducible tissue clearing and labeling workflows.
- Strategic Value: Enables more informed go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery and preclinical assets.
Implementation Considerations
- Requires expertise in tissue handling, immunolabeling, and 3D imaging analysis.
- Needs access to electrophoresis chambers, syringe pumps, and high-resolution imaging platforms.
- Demands cross-team standardization of sample preparation and labeling protocols.
- Adaptable to various organ systems but may require optimization for tissue density and antibody penetration.
- Hydrogel monomer handling necessitates strict safety precautions due to hazardous reagents.
Biopharma FAQs
Why does null hypothesis testing matter for ACT-PRESTO-based target validation?
Null hypothesis testing ensures that observed molecular or structural differences in cleared, immunolabeled tissues are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit into ACT-PRESTO immunolabeling workflows?
Isolating variables such as antibody concentration or clearing duration enables systematic optimization of labeling depth and specificity, ensuring reproducible outputs for downstream R&D decisions.
What do quantitative dependent variable measurements enable in ACT-PRESTO imaging?
Quantitative measurements of labeling depth and signal intensity provide objective criteria for comparing experimental conditions and validating assay performance across tissue samples.
Why are replication requirements critical for cross-functional ACT-PRESTO studies?
Replication ensures that tissue clearing and immunolabeling results are consistent across teams and experiments, supporting reliable data integration and collaborative decision-making in multi-site R&D environments.
Which statistical analysis capabilities are required before implementing ACT-PRESTO in screening pipelines?
Robust statistical tools are needed to analyze 3D imaging data, assess labeling uniformity, and compare treatment groups, enabling confident integration of ACT-PRESTO outputs into screening and discovery workflows.
